Sofwave Safety & Side Effects

Sofwave holds both FDA and KFDA clearance with a documented adverse event rate below 1% across 5,000+ treatments in published clinical data. The SUPERB technology delivers ultrasound at 1.5mm depth with integrated Sofcool cooling, limiting energy exposure to the mid-dermis while protecting the epidermis. Side effects are mild and transient, resolving within 24-72 hours in over 95% of patients.
Sofwave Safety & Side Effects

Sofwave Safety Profile and Regulatory Status

Sofwave received FDA 510(k) clearance in 2021 for lifting the eyebrow, submental, and neck tissue, as well as reducing fine lines and wrinkles. The Korean Ministry of Food and Drug Safety (KFDA) granted parallel clearance, confirming that the device meets rigorous safety standards in both Western and Asian regulatory frameworks. Clinical trials involving over 300 subjects demonstrated measurable improvement in skin laxity with no serious adverse events reported during 12-month follow-up periods.

The SUPERB (Synchronous Ultrasound Parallel Beam) technology operates at 1.5mm depth, specifically targeting the mid-dermis where collagen and elastin fibers are concentrated. Unlike older HIFU devices that penetrate to 3.0-4.5mm, Sofwave avoids the SMAS layer entirely. This shallower targeting reduces the risk of nerve irritation, fat atrophy, and deep tissue bruising that can occur with deeper energy delivery systems.

Common Side Effects and Their Duration

Immediate Reactions (0-24 Hours)

Redness affects approximately 80-90% of patients and typically resolves within 2-4 hours post-treatment. Mild swelling occurs in 30-40% of cases, concentrated around the periorbital and submental regions. A warm or tingling sensation persists for 1-2 hours after the session concludes. These reactions correlate directly with energy output per shot and the total number of shots delivered during treatment.

Short-Term Effects (1-7 Days)

Tenderness when touching treated areas affects roughly 15-25% of patients during days 1-3. This sensation resembles mild muscle soreness and requires no medication in most cases. Temporary skin dryness may appear between days 2-5 as the mid-dermis undergoes thermal remodeling. Applying a hyaluronic acid serum and ceramide moisturizer twice daily mitigates this effect effectively.

Contraindications and Risk Factors

Sofwave treatment is contraindicated for individuals with active skin infections, open wounds, or severe cystic acne in the target area. Patients with implanted electrical devices such as pacemakers or defibrillators should not undergo ultrasound-based treatments. Isotretinoin (Accutane) use within the preceding 6 months increases photosensitivity and healing variability, requiring clearance from a prescribing physician before proceeding.

Pregnancy and breastfeeding represent absolute contraindications due to insufficient safety data in these populations. Patients with a history of keloid scarring require careful assessment, though Sofwave's mid-dermal targeting at 1.5mm carries lower keloid risk than ablative procedures. Fitzpatrick skin types I through VI are all eligible for Sofwave treatment, making it one of the few energy devices safe across the full skin color spectrum.

Clinical Evidence Supporting Sofwave Safety

A prospective multicenter study published in 2022 evaluated 169 subjects receiving Sofwave for facial wrinkle reduction. At 12 weeks post-treatment, 72% of subjects showed measurable improvement on the Fitzpatrick Wrinkle Severity Scale with zero device-related serious adverse events. Persistent side effects beyond 7 days occurred in fewer than 2% of participants. Golbari NM et al. Dermatol Surg. 2022;48(8):869-873. doi:10.1097/dss.0000000000003512

The integrated Sofcool parallel cooling mechanism maintains epidermal temperature below 45 degrees Celsius during energy delivery. This real-time cooling reduces burn risk to near zero when the device is operated according to manufacturer protocols. Practitioners at RE:BERRY Gangnam follow standardized Sofwave protocols with calibrated energy parameters for each facial zone, ensuring consistent safety margins across all treatment sessions.

How to Verify Clinic and Practitioner Qualifications

Qualified Sofwave practitioners hold manufacturer certification confirming completion of device-specific training. In Korea, clinics must be registered medical institutions with physicians licensed by the Korean Medical Association. Patients should verify that the clinic uses a genuine Sofwave device with current calibration records, as counterfeit or modified ultrasound devices lack the safety controls built into authorized units. Asking to see the device serial number and maintenance log provides additional assurance of treatment safety and efficacy standards.

Frequently Asked Questions

Is Sofwave safe for all skin types?
Sofwave treats all 6 Fitzpatrick skin types (I-VI), making it one of the safest energy-based devices for diverse skin tones. The 1.5mm depth targeting bypasses melanin-rich epidermal layers, reducing hyperpigmentation risk to under 1%. Dark skin types that face higher risks with laser treatments tolerate Sofwave without additional precautions.
What are the side effects of Sofwave?
Redness occurs in 80-90% of patients and resolves within 2-4 hours post-treatment. Mild swelling affects 30-40% of cases, fading by day 2-3. Tenderness when touching treated areas persists for 1-3 days in approximately 15-25% of patients. Serious complications such as burns or nerve damage occur in fewer than 0.1% of treatments.
How do I know if a clinic is qualified?
3 verification steps confirm clinic qualifications: check for a valid Korean medical institution registration number, request the practitioner's Sofwave manufacturer training certificate, and ask to see the device serial number with calibration records. Licensed clinics in Korea display their registration publicly and maintain device maintenance documentation.
What certifications should I look for?
2 critical certifications validate Sofwave safety: FDA 510(k) clearance (granted 2021) and KFDA approval from Korea's Ministry of Food and Drug Safety. The practitioner should hold manufacturer-issued device certification. Clinics performing Sofwave should also carry medical liability insurance and employ physicians licensed by the Korean Medical Association.
Are there long-term risks?
12-month follow-up studies show zero serious long-term adverse events among 300+ subjects in clinical trials. Sofwave targets the mid-dermis at 1.5mm depth without reaching fat layers or nerve structures, eliminating risks of fat atrophy and nerve damage. No cases of chronic scarring or permanent skin changes have been documented in peer-reviewed literature.
Who should avoid Sofwave treatment?
6 groups should avoid Sofwave: patients with active skin infections, those with implanted electrical devices like pacemakers, individuals on isotretinoin within the past 6 months, pregnant or breastfeeding women, people with open wounds in the treatment area, and those with severe cystic acne. Medical clearance resolves most temporary contraindications.
How does Sofwave compare to other devices in safety?
Sofwave's adverse event rate stays below 1%, compared to 3-5% for ablative lasers and 2-4% for deeper HIFU devices targeting 3.0-4.5mm. The integrated Sofcool system maintains epidermal temperature under 45 degrees Celsius during treatment. Recovery time averages 2-4 hours versus 5-14 days for ablative procedures.

Book a Consultation

Free consultation. We respond within 24 hours.

Thank you! We will contact you within 24 hours.